Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-9 of 9 (Search time: 0.002 seconds).
previous
1
next
Item hits:
Preview
Issue Date
Title
Author(s)
2009
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
Chuah, C.
;
Vaz de Melo, J.
2009
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1
Chase, A.
;
Schultheis, B.
;
Kreil, S.
;
Baxter, J.
;
Hidalgo-Curtis, C.
;
Jones, A.
;
Zhang, L.
;
Grand, F.
;
Vaz de Melo, J.
;
Cross, N.
2009
Proteasome proteolytic profile is linked to Bcr-Abl expression
Crawford, L.
;
Windrum, P.
;
Magill, L.
;
Vaz de Melo, J.
;
McCallum, L.
;
McMullin, M.
;
Ovaa, H.
;
Walker, B.
;
Irvine, A.
2009
CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression
Batlle, A.
;
Papadopoulou, V.
;
Gomes, A.
;
Willimott, S.
;
Vaz de Melo, J.
;
Naresh, K.
;
Lam, E.
;
Wagner, S.
2009
The impact of gene profiling in chronic myeloid leukaemia
Yong, A.
;
Vaz de Melo, J.
2009
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
Klawitter, J.
;
Kominsky, D.
;
Brown, J.
;
Klawitter, J.
;
Christians, U.
;
Leibfritz, D.
;
Vaz de Melo, J.
;
Eckhardt, S.
;
Serkova, N.
2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford, S.
;
Vaz de Melo, J.
;
Hughes, T.
2009
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL positive cells
Kominsky, D.
;
Klawitter, J.
;
Brown, J.
;
Boros, L.
;
Vaz de Melo, J.
;
Eckhardt, S.
;
Serkova, N.
2009
The level of BCR-ABL1 kinase activity before treatment does not identify myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
Khorashad, J.
;
Wagner, S.
;
Greener, L.
;
Marin, D.
;
Reid, A.
;
Milojkovic, D.
;
Patel, H.
;
Willimott, S.
;
Rezvani, K.
;
Gerrard, G.
;
Loaiza, S.
;
Davis, J.
;
Goldman, J.
;
Vaz de Melo, J.
;
Apperley, J.
;
Foroni, L.
Discover
Author
2
Brown, J.
2
Eckhardt, S.
2
Klawitter, J.
2
Kominsky, D.
2
Serkova, N.
2
Wagner, S.
2
Willimott, S.
1
Apperley, J.
1
Batlle, A.
1
Baxter, J.
.
next >
Subject
3
Benzamides
3
Drug Resistance, Neoplasm
3
Humans
3
Imatinib Mesylate
3
Leukemia, Myelogenous, Chronic, B...
3
Piperazines
3
Pyrimidines
2
Fusion Proteins, bcr-abl
2
K562 Cells
2
tyrosine kinase
.
next >